Cargando…
Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective s...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468778/ https://www.ncbi.nlm.nih.gov/pubmed/34572711 http://dx.doi.org/10.3390/antibiotics10091129 |
_version_ | 1784573758641537024 |
---|---|
author | Brescini, Lucia Della Martera, Filippo Morroni, Gianluca Mazzanti, Sara Di Pietrantonio, Maria Mantini, Paolo Candelaresi, Bianca Pallotta, Francesco Olivieri, Silvia Iencinella, Valentina Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Veccia, Salvatore Cirioni, Oscar Tavio, Marcello Giacometti, Andrea |
author_facet | Brescini, Lucia Della Martera, Filippo Morroni, Gianluca Mazzanti, Sara Di Pietrantonio, Maria Mantini, Paolo Candelaresi, Bianca Pallotta, Francesco Olivieri, Silvia Iencinella, Valentina Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Veccia, Salvatore Cirioni, Oscar Tavio, Marcello Giacometti, Andrea |
author_sort | Brescini, Lucia |
collection | PubMed |
description | Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”. |
format | Online Article Text |
id | pubmed-8468778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84687782021-09-27 Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center Brescini, Lucia Della Martera, Filippo Morroni, Gianluca Mazzanti, Sara Di Pietrantonio, Maria Mantini, Paolo Candelaresi, Bianca Pallotta, Francesco Olivieri, Silvia Iencinella, Valentina Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Veccia, Salvatore Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Antibiotics (Basel) Article Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”. MDPI 2021-09-19 /pmc/articles/PMC8468778/ /pubmed/34572711 http://dx.doi.org/10.3390/antibiotics10091129 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Brescini, Lucia Della Martera, Filippo Morroni, Gianluca Mazzanti, Sara Di Pietrantonio, Maria Mantini, Paolo Candelaresi, Bianca Pallotta, Francesco Olivieri, Silvia Iencinella, Valentina Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Veccia, Salvatore Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
title | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
title_full | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
title_fullStr | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
title_full_unstemmed | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
title_short | Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center |
title_sort | use of dalbavancin in skin, bone and joint infections: a real-life experience in an italian center |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468778/ https://www.ncbi.nlm.nih.gov/pubmed/34572711 http://dx.doi.org/10.3390/antibiotics10091129 |
work_keys_str_mv | AT brescinilucia useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT dellamarterafilippo useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT morronigianluca useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT mazzantisara useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT dipietrantoniomaria useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT mantinipaolo useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT candelaresibianca useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT pallottafrancesco useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT olivierisilvia useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT iencinellavalentina useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT castellettisefora useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT cocciemanuele useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT polorosariag useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT vecciasalvatore useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT cirionioscar useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT taviomarcello useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter AT giacomettiandrea useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter |